Journal of Rheumatology
type: Periodical
type: Information Content Entity
type: Journal
publication venue for: scopus3816
type: Thing
type: Document
type: Collection
type: Continuant
type: Entity
type: Generically Dependent Continuant

Document
type: Class

Continuant
type: Class

Entity
type: Class

scopus3816
most specific type: Document
type: Thing
doi: 10.3899/jrheum.130263
related by: authorship_22014
related by: authorship_22018
volume: 41
related by: authorship_22015
page start: 1077
type: Generically Dependent Continuant
pmid: 24786925
accesstype: All Open Access, Bronze, Green
most specific type: Article
page end: 1087
type: Entity
type: Article
related by: authorship_22017
freetext keyword: Abatacept; Arthritis; Methotrexate; Rheumatoid abatacept; C reactive protein; methotrexate; placebo; steroid; abatacept; antibody conjugate; antirheumatic agent; methotrexate; acrodermatitis; acute lymphoblastic leukemia; adult; amebiasis; aorta rupture; article; asthma; autoimmune disease; basal cell carcinoma; blastocystosis; bronchitis; cardiogenic shock; cerebrovascular accident; chronic drug administration; clinical assessment; clinical effectiveness; colon cancer; controlled study; DAS28; dermatomyositis; disease activity score; disease course; disease duration; dizziness; double blind procedure; drug dose increase; drug efficacy; drug fatality; drug response; drug safety; drug tolerability; drug withdrawal; dyspnea; endometrium cancer; erythema nodosum; female; fever; gastroenteritis; headache; Health Assessment Questionnaire; heart arrest; heart failure; heart infarction; heart muscle ischemia; herpes simplex; human; hypertension; hypotension; hypovolemic shock; hypoxia; infection; influenza; injection site extravasation; injection site swelling; keratoconjunctivitis sicca; large cell neuroendocrine carcinoma; lung alveolus cell carcinoma; lung cancer; lung non small cell cancer; lung tuberculosis; lymphoma; major clinical study; malaria; male; marginal zone lymphoma; melanoma; metastatic melanoma; mite infestation; myelodysplastic syndrome; outcome assessment; parasitosis; pharyngitis; phase 3 clinical trial; pleura effusion; pneumonia; priority journal; prostate cancer; psoriasis; radiography; respiratory failure; retroperitoneal hemorrhage; rheumatoid arthritis; rhinitis; rhinopharyngitis; septic shock; sinusitis; Sjoegren syndrome; squamous cell carcinoma; systemic lupus erythematosus; tachycardia; thorax pain; treatment duration; trichomoniasis; unspecified side effect; upper respiratory tract infection; urinary tract infection; vasculitis; Arthritis, Rheumatoid; drug effects; foot; hand joint; middle aged; randomized controlled trial; retreatment; trea…
related by: authorship_22020
type: Continuant
type: Document
origen: scopus
estado: published
e iscopus: 2-s2.0-84901720853
crisid: 3817
related by: authorship_22022
issue: 6
label: Longterm safety, efficacy, and inhibition of structural damage progression over 5 years of treatment with abatacept in patients with rheumatoid arthritis in the abatacept in inadequate responders to methotrexate trial
related by: authorship_22019
related by: authorship_22016
abstract: Objective. Evaluate the safety and efficacy of longterm abatacept (ABA) treatment over 5 years in methotrexate (MTX)-refractory patients with rheumatoid arthritis (RA). Methods. Patients from the 1-year, double-blind Abatacept in Inadequate Responders to Methotrexate (AIM) study (NCT00048568) received open-label ABA (∼10 mg/kg) in the longterm extension (LTE). Safety was assessed for patients who received ≥ 1 ABA dose, and efficacy for patients randomized to ABA and treated in the LTE. Radiographs were evaluated for changes in Genant-modified Sharp scores. Results. Out of 652 patients, 539 entered the LTE (ABA, n = 378; placebo, n = 161). At Year 5, 72.4%25 were ongoing; discontinuation rates declined over time. Incidence rates of serious adverse events, serious infections, malignancies, and autoimmune events were 13.87, 2.84, 1.45, and 0.99 events/100 patient-years exposure, respectively. American College of Rheumatology 20 response was 82.3%25 (n = 373) and 83.6%25 (n = 268) at years 1 and 5, respectively. Disease Activity Score 28 C-reactive protein (DAS28-CRP) < 2.6 and ≤ 3.2 were achieved by 25.4%25 and 44.1%25 of patients at Year 1 (n = 370), and 33.7%25 and 54.7%25 at Year 5 (n = 267), respectively. Mean changes in DAS28-CRP and Health Assessment Questionnaire-Disability Index at Year 1 [-2.83 (n = 365) and -0.68 (n = 369)] were maintained at Year 5 [-3.14 (n = 264) and -0.77 (n = 271)] for patients continuing treatment. Of them, 59.5%25 (n = 291) and 45.1%25 (n = 235) remained free from radiographic progression at years 1 and 5, respectively. Conclusion. In MTX-refractory patients with RA, longterm ABA treatment was well tolerated and provided consistent safety and sustained efficacy, with high patient retention. Radiographic progression continued to be inhibited with ongoing treatment.
chemicalscas: abatacept, 332348-12-6; C reactive protein, 9007-41-4; methotrexate, 15475-56-6, 59-05-2, 7413-34-5; abatacept; Antirheumatic Agents; Immunoconjugates; Methotrexate
type: Information Content Entity
date time value: article date 3817
has publication venue: Journal of Rheumatology
related by: authorship_22021

Generically Dependent Continuant
type: Class

individual
rights: termsOfUse
date: 2026-08-24T21:50:51
publisher: vivo
type: Document
label: RDF description of Longterm safety, efficacy, and inhibition of structural damage progression over 5 years of treatment with abatacept in patients with rheumatoid arthritis in the abatacept in inadequate responders to methotrexate trial - http://orbis.uaslp.mx/vivo/individual/scopus3816

Article
type: Class

Information Content Entity
type: Class